Share

Lepu Medical Technology Stocks

CN¥ 14.58Last Updated 27.04.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 3.93B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 14.58
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Lepu Medical Technology (Beijing) Co., Ltd. develops, produces, and sells medical devices and equipment. The company offers cardiovascular interventional products, such as coronary stents and balloons, catheters, guide wires, introducer sheaths, tourniquets, inflation devices, and PCI accessories; structural heart diseases products, including occluders, vascular plugs, delivery systems, and mechanical heart valves; cardiac rhythm management products, which include pacemakers, equipment, leads, and electrophysiology; off-pump coronary artery bypass grafting surgical cardiology products; and PTA balloons and guide wires peripheral interventional products. It also provides critical care products, such as vascular access products, needle free connectors, blood samplers, and pressure transducers; floor and suspended type digital subtraction angiography systems; in vitro diagnostic equipment and biomarkers; hemodialysis catheters and hollow fiber dialyzers; and general surgery products, including surgical staplers and endo surgery accessories. In addition, the company offers cardiovascular system drugs, such as antithrombotic, hypolipidemic, antihypertensive, antianginal, and heart failure treatment; ß-lactamase antibiotics and antifungal antimicrobial drugs; central nervous system drugs comprises painkillers and antidepressants; gastric/duodenal ulcer and chronic liver disease treatment drugs; respiratory system drugs; hypoproteinemia drugs; and activating blood circulation drugs. Further, it provides precision medicine, ECG telemonitoring, and cardiovascular disease consulting and management center services; medical S&T incubation and equity investment, and medical financial services; consultation, online pharmacy, and household medical equipment services; smart devices; and specialized hospital services for cardiovascular diseases, as well as involved in the co-construction of Cath lab. The company was founded in 1999 and is headquartered in Beijing, China.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 300003.SZ is 19 and suggests 28% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks